Hope for duchenne: new drug targets rare gene mutation in phase 3 trial

NCT ID NCT07587242

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 6 times

Summary

This study tests an experimental drug called AOC 1044 for boys with Duchenne muscular dystrophy (DMD) who have a specific genetic change (exon 44 skipping). About 70 boys aged 7 to 16 who can still walk will receive either the drug or a placebo. The main goal is to see if the drug helps them stand up faster after 54 weeks of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HP Hospital Armand-Trousseau

    RECRUITING

    Paris, France

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universitario Cattolica del Sacro Cuore

    RECRUITING

    Roma, Italy

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    RECRUITING

    Milan, Italy

  • Hospital Sant Joan de Deu

    RECRUITING

    Barcelona, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, Spain

  • Hospital Viamed Santa Angela De la Cruz - FutureMeds Spain

    RECRUITING

    Seville, Spain

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen

    RECRUITING

    München, Germany

  • Royal Victoria Infirmary

    RECRUITING

    Newcastle, United Kingdom

  • Universitaetsklinikum Essen

    RECRUITING

    Essen, Germany

  • Universitaetsklinikum Heidelberg

    RECRUITING

    Heidelberg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.